TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03934788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxysoft (olifilcon C)
Description: subjects meet certain criteria will be administered randomly oxysoft on both eye for one month on daily wear single use modality.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Si-Hy (olifilcon B)
Description: subjects meet certain criteria will be administered randomly Si-Hy on both eye for one month on daily wear single use modality.
Study: NCT02963805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity physical activity (HIPA)
Description: This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (\~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fundamental movement skill (FMS)
Description: This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity signposting (PASS)
Description: A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
Study: NCT00847327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Support
Description: The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
Study: NCT01989468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Secukinumab placebo provided in 1 mL autoinjector
Study: NCT02451371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
Study: NCT00847327

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
Study: NCT01526668

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up strategy
Description: Comparison of different follow-up strategies
Study: NCT04340141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study: NCT01526668

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up strategy
Description: Comparison of different follow-up strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up strategy
Description: Comparison of different follow-up strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No contact after discharge
Study: NCT05276661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAC/Collagen gel
Description: Apply it twice per day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo lotion
Description: Apply it twice per day for 4 weeks
Study: NCT01820325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buparlisib placebo
Description: Placebo + Carboplatin + Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study: NCT02170662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Description: Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Description: Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03705182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence visualization (feedback)
Description: UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
Study: NCT00720928

Intervention type: DRUG
Group type: OTHER
Intervention: flucinolone acetonide
Description: Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
Study: NCT02401737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVR 3-778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVR 3-778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NVR 3-778
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Study: NCT04405375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabin
Description: 1.25g/㎡ d1, repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500IU/㎡ d1, total dose=\<3750IU, repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 75mg/㎡ d1-3, repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg d1-4
Study: NCT02801214

Intervention type: OTHER
Intervention: fMRI

Intervention type: OTHER
Intervention: fMRI
Study: NCT00690885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha lozenges
Description: 150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo lozenges
Description: matching placebo lozenges
Study: NCT04224805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone-borne CAD/CAM splint
Description: 3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D interocclusal conventional splint
Description: Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
Study: NCT01136499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 (Panobinostat®)
Description: 40 mg MWF.~40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity.
Study: NCT00248703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 100 mg/m2 3 qw x 6
Study: NCT00809380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental presence
Description: Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
Study: NCT02710357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Overdenture
Description: Placement of an implant in the mandibular midline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular complete denture
Description: No intervention. Maintenance of the dentures will be done when needed.
Study: NCT01484067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch ( Compeed© Total CareTM Cold Sore Patch)
Description: A cold sore patch containing zinc sulfate
Study: NCT00159432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT04193371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Description: The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle management
Description: All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lifestyle management
Description: All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week.
Study: NCT00841763

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (PL)
Description: One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle, preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIV)
Description: A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted monovalent influenza virus vaccine (aH5N1)
Description: Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted trivalent influenza virus vaccine (aTIV)
Description: Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
Study: NCT03005054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft Skin Tissue
Description: StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autograft
Description: The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
Study: NCT03011658

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: venepuncture
Description: for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus

Intervention type: PROCEDURE
Group type: OTHER
Intervention: venepuncture
Description: for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
Study: NCT00983983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxepa
Description: Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jevity 1.5
Description: Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Jevity 1.0
Description: Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
Study: NCT03995264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound -guided cannulation
Description: radial artery cannulation using the ultrasound

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Palpation -guided cannulation
Description: radial artery cannulation using the palpation
Study: NCT04270929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriSalus Infusion System
Description: The TriSalus Infusion System administers therapeutics using PEDD technology.
Study: NCT02257190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: One hour of rest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW3
Description: A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW1
Description: A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
Study: NCT01236430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin 10mg/10mg FDC
Description: Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin 10mg/80mg FDC
Description: Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
Study: NCT04219150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical cardiometry
Description: Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid and Catheter Treatment Trial FACTT Lite
Description: The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
Study: NCT02630238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched-Chain Amino Acid Supplementation
Description: All participants will partake in the same diet \& exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will partake in the same diet \& exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.